EMA/492665/2013

European Medicines Agency decision

P/0229/2013

of 23 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for Purified Tetanus Toxoid / Inactivated Type 1 Poliovirus (Mahoney) / Inactivated Type 2 Poliovirus (MEF-1) / Inactivated Type 3 Poliovirus (Saukett) / Purified Pertussis Toxoid (PT) / Haemophilus influenzae type b polysaccharide conjugated to tetanus protein / Purified Filamentous Haemagglutinin (FHA) / Hepatitis B Surface Antigen, recombinant (HBsAg) / Purified Diphtheria Toxoid (DTaP-IPV-HepB-PRP-T) (Hexacima and associated names), (EMEA-001201-PIP01-11-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0229/2013

of 23 September 2013

on the acceptance of a modification of an agreed paediatric investigation plan for Purified Tetanus Toxoid / Inactivated Type 1 Poliovirus (Mahoney) / Inactivated Type 2 Poliovirus (MEF-1) / Inactivated Type 3 Poliovirus (Saukett) / Purified Pertussis Toxoid (PT) / Haemophilus influenzae type b polysaccharide conjugated to tetanus protein / Purified Filamentous Haemagglutinin (FHA) / Hepatitis B Surface Antigen, recombinant (HBsAg) / Purified Diphtheria Toxoid (DTaP-IPV-HepB-PRP-T) (Hexacima and associated names), (EMEA-001201-PIP01-11-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0015/2012 issued on 24 January 2012, and the decision P/0082/2012 issued on 3 May 2012,

Having regard to the application submitted by Sanofi Pasteur on 16 May 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 August 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptanceof changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for Purified Tetanus Toxoid / Inactivated Type 1 Poliovirus (Mahoney) / Inactivated Type 2 Poliovirus (MEF-1) / Inactivated Type 3 Poliovirus (Saukett) / Purified Pertussis Toxoid (PT) / Haemophilus influenzae type b polysaccharide conjugated to tetanus protein / Purified Filamentous Haemagglutinin (FHA) / Hepatitis B Surface Antigen, recombinant (HBsAg) / Purified Diphtheria Toxoid (DTaP-IPV-HepB-PRP-T) (Hexacima and associated names), suspension for injection, intramuscular use are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Sanofi Pasteur SA, 2 avenue Pont Pasteur, 69007 – Lyon, France.

Done at London, 23 September 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/310170/2013 Corr

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001201-PIP01-11-M02

Scope of the application

Active substance(s):

Purified Tetanus Toxoid / Inactivated Type 1 Poliovirus (Mahoney) / Inactivated Type 2 Poliovirus (MEF-1) / Inactivated Type 3 Poliovirus (Saukett) / Purified Pertussis Toxoid (PT) / Haemophilus influenzae type b polysaccharide conjugated to tetanus protein / Purified Filamentous Haemagglutinin (FHA) / Hepatitis B Surface Antigen, recombinant (HBsAg) / Purified Diphtheria Toxoid (DTaP-IPV-HepB-PRP-T)

Invented name:

Hexacima and associated names

Condition(s):

Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, Haemophilus influenzae type b and Hepatitis B virus

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Intramuscular use

Name/corporate name of the PIP applicant:

Sanofi Pasteur SA

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Sanofi Pasteur SA submitted to the European Medicines Agency on 16 May 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0015/2012 issued on 24 January 2012, and the decision P/0082/2012 issued on 3 May 2012.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 June 2013.

Scope of the modification

Some measures and timelines of the agreed Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 9 August 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: prevention of infection caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2, and 3, Haemophilus influenzae type b, and hepatitis B virus.

The waiver applies to:

- Subsets of the paediatric population from birth to less than 6 weeks of age and from 2 years to less than 18 years of age;
- for suspension for injection, intramuscular route;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

2. Paediatric Investigation Plan

2.1. Condition: prevention of infection caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2, and 3, Haemophilus influenzae type b, and hepatitis B virus

2.1.1. Indication(s) targeted by the PIP

Active immunisation against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive infections caused by Haemophilius influenzae type b (such as meningitis, septicaemia, cellulitis, arthritis, epiglottitis, pneumopathy, osteomyelitis).

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 weeks to less than 2 years of age.

2.1.3. Pharmaceutical form(s)

Suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	15	**Study 1 (A3L04):** Randomized, controlled, observer-blind, 4-arm, parallel groups trial to assess incidence of fever and immunogenicity of DTaP-IPV-HepB-PRP-T vaccine as compared to Tritanrix HepB/Hib + oral polio vaccine (schedule 2, 4, 6).

Area	Number of measures	Description
		Study 2 (A3L10): Randomized open-label controlled, 2-arm trial to compare immunogenicity against Hep B of DTaP-IPV-HepB-PRP-T vaccine as compared to Pentaxim and Engerix B (schedule 2, 3, 4). **Study 3 (A3L22):** Open-label extension study of study 2 (A3L10). **Study 4 (A3L11):** Randomized, observer-blind, controlled, 4-arm, lot-to-lot consistency trial (schedule 2, 4, 6). **Study 5 (A3L21):** Open-label, extension study of study 4 (A3L11). **Study 6 (A3L12):** Randomized, observer-blind, controlled study to compare immunogenicity of DTaP-IPV-HepB-PRP-T vaccine to Infanrix Hexa (schedule 2, 4, 6). **Study 7 (A3L15):** Randomized open-label, controlled, 3-arm trial to compare DTaP-IPV-HepB-PRP-T vaccine to CombAct Hib/Engerix/OPV (schedule 6, 10, 14 weeks) including booster phase at 15-18 months. **Study 8 (A3L17):** Randomized, observer-blind, controlled, 2-arm trial to compare DTaP-IPV-HepB-PRP-T vaccine to Infanrix Hexa (schedule 2, 4, 6). **Study 9 (A3L24):** Randomized, observer-blind, 4-arm, lot-to-lot consistency trial of DTaP-IPV-HepB-PRP-T vaccine co-administered with Prevenar and Rotarix (schedule 2, 4, 6). **Study 10 (A3L26):** Randomized, observer-blind extension study of study 7 (A3L15). **Study 11 (A3L27):** Randomized, observer-blind extension study of study 9 (A3L24). **Study 12 (A3L28):** Open-label extension study of study 11 (A3L27). **Study 13 (A3L38):** Randomized, observer-blind, 2-arm trial to compare DTaP-IPV-HepB-PRP-T vaccine to Infanrix Hexa (schedule 3, 5, 12) administered with PCV-13.

Area	Number of measures	Description
		Study 14 (A3L39): Randomized, observer-blind, 2-arm trial to compare DTaP-IPV-HepB-PRP-T vaccine to Infanrix Hexa (schedule 2, 3, 4) administered with PCV-13. **Study 15 (A3L40):** Extension trial of study 14 (A3L39).

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By December 2015.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition and authorised indication:

1. Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus types 1, 2 and 3, Haemophilus influenzae type b and Hepatitis B virus

   Authorised indication:

   - Primary and booster vaccination of infants and toddlers from six weeks to 24 months of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).

Authorised pharmaceutical form(s):

Suspension for injection in pre-filled syringe

Authorised route(s) of administration:

Intramuscular use